| Products and Services |
Categories |
BIOMEDICAL DISCOVERY
Based on its proprietary TEIPP1 technology, Accuro develops active immunotherapies directed at escape variants of several cancers.
The company has established preclinical proof-of-concept and is currently validating lead candidates for its clinical program. The company’s pipeline includes cell-based as well as molecular cancer vaccines based on the TEIPP technology. |
|
Fields marked as * are mandatory
|
|
| *Message |
|
| Contact Details |
Karolinska Science Park
Fogdevreten 2
Stockholm
SE-171 77
Sweden
Tel: 46-70-968-76-01 |
|
| *Request
Type |
|
| *Email |
|
| *First
Name |
|
| *Last
Name |
|
| Address 1 |
|
| Address 2 |
|
| City |
|
| State |
|
| *Country |
|
| Zip |
|
| *Organization |
|
| *Telephone |
|
| Extension |
|
| Designation |
|
| Other |
|
|
Industry |
|
|
Other |
|
Preferred
Method Of
Contact |
If Other
Specify
|
|
|
